Search
Now showing items 1-10 of 12
Prostate specific membrane antigen and DNA damage repair in advanced prostate cancer
(Institute of Cancer Research (University Of London), 2022-03-31)
Identification and implementation of novel therapeutic strategies for advanced prostate cancer (PCa) remains an urgent, unmet clinical need. Prostate Specific Membrane Antigen (PSMA), a PCa biomarker, is currently being ...
An evaluation of contouring and planning methods to expand the role of SBRT with CyberKnife in the treatment of localised prostate and renal cancers
(Institute of Cancer Research (University Of London), 2022-05-31)
Technological advancement has led to the substantial evolution of stereotactic body radiotherapy (SBRT). The CyberKnife SBRT platform achieves a high degree of precision through robotic delivery of multiple non-coplanar ...
Identification of novel targets for the treatment of endocrine-resistant breast cancer
(Institute of Cancer Research (University Of London), 2022-05-31)
While endocrine therapy is an effective, well-tolerated treatment for oestrogen receptor positive (ER-positive) breast cancer, a large proportion of initial responders will develop hormone therapy resistance, and relapse. ...
Biomarkers of therapy response and resistance in clear cell renal cell carcinoma AND Adaptive immune response to SARS-CoV-2 and COVID-19 vaccines in cancer patients
(Institute of Cancer Research (University Of London), 2022-04-30)
The cornerstone of treatment for metastatic clear cell renal cell carcinoma (ccRCC) are anti-VEGF and/or immune checkpoint inhibitors (CPI). However, there are no clinically implemented predictive biomarkers in any therapeutic ...
Targeting the tumour microenvironment with endosialin-directed CAR T-cells
(Institute of Cancer Research (University Of London), 2022-05-31)
Advances in T-cell engineering have facilitated the generation of CAR T-cells that successfully deplete malignant cells of haematological cancers. However, attempts to target solid tumours with CAR T-cells have been hindered ...
Exploiting the CRL4-CRBM E3 ubiquitin ligase complex for the development of iTAG: a versatile targeted protein degradation system to enable functional evaluation and target validation
(Institute of Cancer Research (University Of London), 2022-02-28)
Modulating target protein expression to probe for its relevance and function in a disease is critical in the drug discovery process of target validation. Current genetic methods and chemico-biology tools are widely employed ...
Amino acid dependence in acute myeloid leukaemia
(Institute of Cancer Research (University Of London), 2022-05-31)
Acute myeloid leukaemia (AML) is a heterogeneous disease which remains curable in only a minority of patients. Outcome is dismal in the subgroup with adverse genetic features. Amino acid (AA) depletion is a therapeutic ...
Monitoring tumour response to extracellular matrix modulation with multiparametric MRI
(Institute of Cancer Research (University Of London), 2022-04-30)
Primary breast tumours are characterised by a dense extracellular matrix (ECM), with accumulation of collagen and hyaluronan (HA). This stromal dense phenotype is associated with tumour progression, metastasis and poor ...
Mathematical modelling of subclonal interactions in paediatric high-grade gliomas
(Institute of Cancer Research (University Of London), 2022-05-31)
Despite a low overall mutational burden, paediatric high-grade gliomas (pHGG) display high intra-tumour heterogeneity. Accumulating evidence suggest the presence of cellular mechanisms that maintain such high heterogeneity, ...
Local therapeutic approaches for the management of recurrent gynaecological cancer
(Institute of Cancer Research (University Of London), 2022-02-28)
Surgery, radiotherapy and chemotherapy combinations are used to treat recurrent gynaecological malignancy. Stereotactic body radiotherapy (SBRT) delivered to the involved surgical margin could improve clinical outcomes ...